SAB Biotherapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing multi specific high potency human immunoglobulin G to treat and prevent immune and autoimmune disorders. The company uses a proprietary platform based on transchromosomic cattle known as Tc Bovine to produce fully human antibodies without relying on human donors or convalescent plasma. Its lead product candidate SAB 142 targets autoimmune type 1 diabetes with a disease modifying approach designed to delay onset and preserve pancreatic beta cell function.

As a clinical stage company SAB Biotherapeutics, Inc. does not yet generate revenue from product sales. Its funding comes primarily from government awards research collaborations and licensing agreements. The company has received over two hundred million dollars in grants from U. S. government programs focused on emerging diseases and medical countermeasures.

SAB Biotherapeutics, Inc. occupies a niche in the immunotherapy sector where it develops polyclonal human immunoglobulin G products that mimic the function of anti-thymocyte globulin while avoiding the immunogenicity associated with animal derived versions. Its main competitors include larger biopharmaceutical firms such as Sanofi S. A. and emerging companies like Sana Biotechnology Imcyse vTv Therapeutics Century Therapeutics IM Therapeutics Sernova and Biomea Fusion. The company’s competitive advantage stems from its proprietary Tc Bovine platform which enables large scale production of fully human antibodies without a biosimilar pathway creating high barriers to entry for potential rivals.

Since the company has not yet commercialized any product its customers are primarily clinical trial sites patients enrolled in its studies and research institutions with which it collaborates. In the future it expects to serve hospitals specialty clinics and healthcare providers that treat patients with autoimmune disorders such as type 1 diabetes.